argenx SE (ARGX) Expands Autoimmune Leadership with Vyvgart Launch

Company Overview - argenx SE (NASDAQ:ARGX) is enhancing its position in autoimmune therapies with the rapid growth of its flagship treatment, Vyvgart, which is available in both intravenous and subcutaneous forms [2] Product Development - The launch of the Vyvgart subcutaneous prefilled syringe in 2025 has been a significant highlight, gaining popularity as a convenient alternative to infusions, particularly in chronic inflammatory demyelinating polyneuropathy (CIDP) [3] - Over 2,500 patients have already started treatment with Vyvgart in CIDP this year, indicating strong adoption in the U.S. market [3] - Additional approvals for Vyvgart in Japan and Canada are anticipated by the end of the year, which will further expand its global presence [3] Market Potential - Vyvgart is positioned as one of the fastest-growing biologics in generalized myasthenia gravis (gMG) and other autoimmune diseases, with analysts forecasting multibillion-dollar peak sales [4] - Upcoming Phase 3 trial results in late 2025 and early 2026 for seronegative gMG, ocular and pediatric MG, and primary immune thrombocytopenia (ITP) could lead to broader label expansions and reinforce its status as a standard of care [4] Pipeline Expansion - Beyond Vyvgart, argenx SE is developing a diverse pipeline that includes early-stage candidates such as empasiprubart, ARGX-109, and ARGX-119 targeting autoimmune and rare neuromuscular diseases [5] - The company is also exploring new modalities through partnerships, including a recent collaboration with Unnatural Products to create oral peptide therapies [5]